EarningsQ1 2026 Earnings Report
DE:TKD Q1 2026 EPS Results
Actual EPS€0.40
Consensus EPS€0.31
Beat/MissBeat by +€0.10
One Year Ago EPS€0.45
DE:TKD Q1 2026 Revenue Results
Actual Revenue€6.87B
Expected Revenue€6.47B
Beat/MissBeat by +€395.98M
YoY Revenue Growth+10.23%
Earnings Announcement Details
QuarterQ1 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
DE:TKD Upcoming Earnings
Takeda Pharmaceutical Co's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q1 2026 Earnings Call Audio
DE:TKD Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mix of modest near-term CER declines and cash-flow timing effects against substantial positive developments: strong FX-driven reported results, confirmation of transformation-led funding for launches, multiple imminent regulatory and commercial milestones (ORZEYFUL approval in China; rusfertide priority review; superior zasocitinib data), and a robust late-stage pipeline with several programs moving to pivotal stages. While Q1 contained some one-time impacts, transitional investment effects and product-specific headwinds, the combination of pipeline momentum, launch readiness and a maintained full-year financial outlook suggests the company is positioned to convert R&D progress into revenue growth later in the year.Company Guidance
Top-Line Growth at Actual FX
Reported revenue JPY 1.22 trillion, up 10.2% on an actual FX basis (but -0.5% at constant exchange rates (CER)); FX tailwind added JPY 118.2 billion to revenue.
Core Operating Profit Supported by FX
Core operating profit JPY 358.9 billion, up 11.5% at actual FX (but -0.5% at CER), reflecting favorable currency translation and partial offsetting of growth investments by transformation savings.
Strong Performance of Core In-Line Brands and Key Products
Core in-line brands represented 58% of revenue and grew 2.3% at CER; ENTYVIO grew 4% at CER; new launches (currently 4% of revenue) grew 22.6% at CER, driven by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA.
Pipeline and Regulatory Milestones — ORZEYFUL Approval in China
First approval for orexin agonist oveporexton (ORZEYFUL) in China for narcolepsy type 1; U.S. and Japan decisions expected imminently (company preparing launches in H2 2026).
Late-Stage Assets with High Potential — Rusfertide and Zasocitinib
Rusfertide (hepcidin mimetic for polycythemia vera) received U.S. FDA priority review with an August PDUFA and anticipated U.S. launch in H2 2026; zasocitinib (oral TYK2 inhibitor for psoriasis) showed statistical superiority vs deucravacitinib with >35% PASI 100 at week 16 and is on track for U.S. launch in H1 2027.
Additional R&D and Oncology Progress
TAK-928 presented promising ASCO data (NSCLC) with plans for a pivotal Phase III; elritercept initiated Phase III in first-line anemia-associated MDS; TAK-921 and TAK-881 advancing toward regional filings and U.S. submission for PDT indications.
Financial Discipline and Full-Year Cash Guidance Maintained
Company reaffirmed fiscal 2026 outlook and free cash flow guidance of JPY 650 billion to JPY 750 billion; transformation program underway to fund launches while protecting margins and targeting ROE improvement above 5%.
DE:TKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed